Buzzwords, like a virus, spread inexorably from discipline to discipline. Take “big data,” which originated in supercomputing and now has infected finance, logistics, intelligence and defense and life science. Is there some rule requiring every presentation on genomics to include a slide comparing sequencing costs to Moore’s Law, followed by slides lamenting how much data we are producing and the resources required to act on it?
On the eve of the 25th World AIDS Day (December 2014), President Barack Obama expressed hope to our nation, proclaiming that an “AIDS-free generation is within our reach.” During his speech, Obama expressed how our nation has made significant strides toward strengthening scientific investments, building effective HIV/AIDS education and prevention programs and bringing together public and private stakeholders.
In the U.S. about 12,500 women are diagnosed with cervical cancer a year. Out of these women, about 4,500 progress into invasive cervical cancer or the end stage of the disease. This leaves about 8,000 women a year in the U.S. that are cured through existing standard of care treatment: surgery or chemotherapy/radiation. However, chemotherapy/radiation have terrible side effects in some cases.
Many companies have recognized an untapped opportunity for improving their development process: the requirements traceability matrix. Rather than wait until the end of the development cycle, the team builds the trace matrix when requirements first go under design control, and maintains it all the way through the submission process.
Laboratories are like a living organism: They need to breathe to survive. Air exchange and management is one of a laboratory’s primary functions, and like the creature that breathes with lungs, the research environment contains many cells, or pockets, of both pure and contaminated air. These enclosures protect specimens or samples from the deleterious effects of contaminated air and allow researchers to breathe freely.
In an editorial cartoon that appeared in a recent issue of The Journal of Clinical Investigation, a surgeon wields a scalpel over his patient. The caption reads: “Just a little nip here and there. We don’t want it to look like it’s had any work done.” The catch? The patient is a western blot, and the doctor is presumably making his patient look presentable for publication in a peer-reviewed journal.
The biggest challenges many elite enterprises face are actually external forces completely out of their control, from geopolitical and economic macro trends to global threats to health and the environment. This lack of control creates a tumultuous global business climate that conspires to unravel even the most well-thought-out strategic plans.
Stem cell research has been breaking ground in new application areas over the past few years, and it’s poised for even greater growth as more companies and organizations realize the potential. In the next decade, cell-based therapies will become increasingly common for cancer, immunological disorders, cardiac failure and other conditions.
Progress often requires change. For protein-based diagnostics, multiplexed assays and detection of protein isoforms will drive the adoption of a new strategy for diagnostic testing, called immuno-MS. Enzyme-linked immunosorbent assays (ELISA) have become the standard for antibody-based diagnostic tests in clinical settings. ELISAs provide specific detection of biomarkers through use of antibodies which target specific epitopes on antigens.
Medical laboratory test results provide physicians with vital information needed for accurate diagnosis, treatment and monitoring of patients. An estimated 60 to 70% of all decisions regarding a patient’s diagnosis and treatment, hospital admission and discharge are based on laboratory test results.
Laboratory automation techniques are commonplace, as they improve the accuracy and repeatability of laboratory operations, reduce human error in these operations and reduce cost of these operations. Defined as the use of technology to streamline or substitute manual manipulation of equipment and processes, laboratory automation offers solutions for enhancing workflows in various research laboratory environments.
Microscopy is growing at a rapid rate as the result of substantial investment in nanotechnology research. Advances in nanotechnology not only support advances in materials technology, they support developments in the semiconductor and medical devices industries. These billions of dollars drive support for advanced microscopy technologies, which are expected to become a $5 to 6 billion market globally by 2018.
As interest and investment in biopharmaceuticals grows, the pressure to innovate and rapidly deliver new therapies increases. While many avenues may be pursued, the high cost of developing biological molecules increases the need to advance only those therapies with the greatest likelihood of becoming manufacturable, efficacious, safe and profitable products.
Awareness of the benefits of gravimetric sample preparation has increased significantly over the past couple of years. Recognition of this state-of-the-art technology by industry organizations such as the United States Pharmacopeia (USP) has supported this trend. A recent revision to USP chapter 1251 “Weighing on an Analytical Balance” included a detailed description of the steps involved in gravimetric dosing for sample preparation.
The benefits of flow cytometry are well known. The popular technique allows researchers to explore data on a cell-by-cell basis, as opposed to other analysis methods which only offer population-based or averaged information. In addition, flow cytometry can give users absolute percentages of what each marker or dye is reporting.